



Press release

## FINANCIAL COMMUNICATIONS SCHEDULE FOR THE FIRST HALF OF 2015

**SOPHIA ANTIPOLIS, France - January 23, 2015** - MEDIAN Technologies (FR0011049824, ALMDT) (ALMDT), a leading medical imaging solutions and service provider for image interpretation and management in oncology clinical trials, cancer screening programs and routine practice in oncology, announces the publication date for its 2014 results:

Publication	Date
2014 results	April 15, 2015*

*\*Distribution after the close of trading*

Following publication, a luncheon will be held for Investors on April 16, 2015 to present the results.



**About MEDIAN Technologies:** MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care. MEDIAN has a strategic partnership with the world's largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia. MEDIAN has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market. (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup. For more information on MEDIAN, please visit: [www.mediantechologies.com](http://www.mediantechologies.com)



# MEDIAN

*“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”*



## Contacts

<b>MEDIAN Technologies</b> Fredrik Brag, CEO +33 4 92 90 65 82 <a href="mailto:fredrik.brag@mediantechnologies.com">fredrik.brag@mediantechnologies.com</a>	<b>Press</b> <b>ALIZE RP</b> Caroline Carmagnol Sophie Colin + 33 1 44 54 36 66 <a href="mailto:median@alizerp.com">median@alizerp.com</a>	<b>Investors</b> <b>ACTIFIN</b> Ghislaine Gasparetto <a href="mailto:ggasparetto@actifin.fr">ggasparetto@actifin.fr</a> +33 1 56 88 11 11
--	---	---